Mount Sinai-Clinique Healthy Skin Dermatology Center Launched through Collaboration

Clinique and the Icahn School of Medicine at Mount Sinai have joined forces in a philanthropic venture to establish the groundbreaking Mount Sinai-Clinique Healthy Skin Dermatology Center. This collaborative effort aims to pioneer innovative research in dermatology, delving into the biological foundations of skin aging, allergies, and various inflammatory skin conditions, including eczema (atopic dermatitis) and contact dermatitis.

United by a common mission to advance dermatological research for the betterment of patients’ lives, the partnership will emphasize practical scientific discoveries and cutting-edge innovations to revolutionize allergy science. The primary focus is on identifying inventive solutions for allergic skin conditions through the acceleration of research findings. The ultimate goal is to bridge the gap between basic scientific knowledge and real-world applications in clinics, thereby enhancing people’s lives by promoting healthy skin.

The Mount Sinai-Clinique Healthy Skin Dermatology Center will investigate healthy skin as well as the skin of individuals with atopic dermatitis and other allergic skin disorders. This comprehensive approach seeks to not only alleviate allergic skin conditions but also uncover insights that may significantly slow the visible signs of aging, particularly in patients with eczema who exhibit premature or accelerated aging. The outcomes of this research are anticipated to drive advancements in dermatology and skin health, influencing Clinique’s future product innovations to provide additional solutions for individuals with allergic or sensitive skin.

Michelle Freyre, President of Global Brands at Clinique, expressed pride in partnering with the esteemed Icahn Mount Sinai institution and its team of physician-scientists, led by the renowned expert in allergic and inflammatory skin diseases, Dr. Emma Guttman. Freyre highlighted Clinique’s commitment to dermatologist-guided and allergy-tested solutions and expressed confidence in the groundbreaking research that will result from this unique collaboration.

Dr. Emma Guttman, a trailblazer in dermatologic science, emphasized the impact of chronic inflamed skin on premature aging. Drawing on extensive research, Dr. Guttman aims to actively explore targeted approaches to reverse eczematous and allergic skin conditions, with the overarching goal of creating and sustaining healthy skin. The partnership with Clinique will provide crucial support for these endeavors, contributing to the understanding and prevention of age-related inflammation, or ‘inflammaging.’

The Icahn Mount Sinai laboratory of Inflammatory Skin Diseases, under Dr. Guttman’s leadership, has made paradigm-shifting discoveries in atopic dermatitis and other inflammatory skin diseases. Their work has led to the development of comprehensive molecular maps of atopic dermatitis, shaping the landscape of therapeutics for this condition and solidifying their position as leaders in global dermatology and immunology.

Clinique’s history of collaboration with dermatologists and its commitment to innovation, dating back to its Founding Dermatologist, Dr. Norman Orentreich, is emphasized. The Orentreich family’s ongoing involvement in Clinique, with Dr. David Orentreich serving as Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, further strengthens the brand’s dedication to dermatological excellence.

In alignment with their mission, Clinique has pledged a philanthropic contribution of $5 million over seven years to support allergy science’s advancement through the Mount Sinai-Clinique Healthy Skin Dermatology Center. These funds will be utilized to recruit top-notch physicians and scientists, procure advanced equipment, establish clinical and laboratory space, and hire essential support staff. The studies conducted by the center will encompass diverse demographics, investigating factors such as diet, exercise, and stress on healthy skin. The partnership’s collective efforts are anticipated to expedite critical breakthroughs in the early stages of this multiyear initiative.

Source Link